Business Context and Reporting Period
Company: Prothena Corporation plc
Filing Type: Form 8-K (Current Report)
Date of Report: June 24, 2014
Event: Entry into a Material Definitive Agreement (Underwriting Agreement) for an initial public offering of ordinary shares.
Key Financial Metrics
This filing details a capital raise rather than operational performance metrics. Key figures include:
- Shares Offered: 4,750,000 ordinary shares.
- Public Offering Price: $22.50 per share.
- Underwriting Price: $20.925 per share (excluding shares purchased by Woodford Investment Management LLP).
- Woodford Investment Management LLP Purchase: 2,222,222 shares purchased at the public offering price without underwriting discount.
- Expected Net Proceeds: Approximately $102.5 million (after underwriting discount and estimated expenses).
- Over-Allotment Option: Underwriters granted a 30-day option to purchase up to 712,500 additional shares.
Note: The filing does not provide data on revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
The primary material change is the execution of the Underwriting Agreement on June 24, 2014, with Merrill Lynch, Pierce, Fenner & Smith Incorporated, Credit Suisse Securities (USA) LLC, and RBC Capital Markets, LLC as representatives. This agreement facilitates the sale of the Company's ordinary shares to the public.
Guidance, Outlook, and Risks
Management Commentary: The offering is being made pursuant to previously filed registration statements on Form S-3 (Reg. Nos. 333-196965 and 333-197006). The Underwriting Agreement contains customary representations, warranties, covenants, indemnification provisions, and contribution provisions.
Risks and Contingencies: The receipt of net proceeds is subject to customary closing conditions. The filing does not explicitly list specific operational risks or contingencies beyond the standard conditions of the underwriting agreement.
Investor Verification Checklist
- Verify the final closing of the offering and the actual net proceeds received.
- Confirm whether the underwriters exercised the 30-day over-allotment option for the additional 712,500 shares.
- Review the full Underwriting Agreement (Exhibit 1.1) for specific covenants and indemnification details.
- Check subsequent filings for the use of proceeds and any impact on the Company's capital structure.